Vaxxas Recognized as 2012 Janssen AusBiotech Emerging Company of the Year
October 31, 2012
BRISBANE, QLD, AUSTRALIA
Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today it has received the 2012 Janssen AusBiotech Emerging Company of the Year Award. This award recognizes Vaxxas' significant technological achievements, and efforts to foster growth in the biotechnology industry.
"We thank Janssen and AusBiotech for recognizing Vaxxas through this award," said David Hoey, Chief Executive Officer of Vaxxas. "We are working to advance the company by continuing to invest significantly in our core science, growing our team to support preclinical programs, and establishing relationships with key industry partners." The Company recently announced its first collaboration with Merck.
Vaxxas was founded in August 2011 with the completion of a A$15M Series A equity financing. More than 20 scientists and engineers are now working to progress the Vaxxas' Nanopatch™ platform toward first clinical demonstrations. The company recently opened a commercialization office in Cambridge, Massachusetts, to expand access to global pharmaceutical partners and complement the company's research and development operations based in Queensland, Australia.
Vaxxas is a privately-held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas' Nanopatch™contains an ultra-high density array of projections - invisible to the naked human eye - that are dry-coated with vaccine. Application of the Nanopatch™to the skin is pain free and rapidly delivers the vaccine to the abundant immune cell population immediately below the skin surface. In a wide range of preclinical studies Nanopatch™delivery of vaccine achieves equivalent protective immunity as the needle and syringe - but with only 1/100th of the dose. It has also been shown that Vaxxas' proprietary dry-coating technology can eliminate the need for vaccine refrigeration during storage and transportation - removing the resource burden of maintaining the "cold chain". Leveraging both the potent immunogenic response and thermostability, Vaxxas is applying its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology. The company recently announced its first collaboration with Merck.
Vaxxas' Nanopatch™technology originated from Professor Mark Kendall's research group at the Australian Institute of Bioengineering and Nanotechnology at The University of Queensland, the Australian university where some of the groundbreaking immunological work on human papilloma virus vaccines was performed. The University of Queensland's main commercialization company, UniQuest, led the initial commercialization of the Nanopatch™technology prior to the creation of Vaxxas in 2011. Vaxxas is backed by a strong group of venture investors including OneVentures, Brandon Capital, Healthcare Ventures, and the Medical Research Commercialisation Fund.
The company is initially focused on partnering with leading vaccine companies who are seeking a needle-free, differentiated, high performance, cost effective and safe vaccine delivery platform.